ISIN | LU1585228379 |
---|---|
Valor Number | |
Bloomberg Global ID | |
Fund Name | Bellevue Emerging Markets Healthcare I2 |
Fund Provider |
Bellevue Asset Management AG
Zürich, Switzerland Phone: +41 44 267 67 00 E-Mail: info@bellevue.ch Web: www.bellevue.ch |
Fund Provider | Bellevue Asset Management AG |
Representative in Switzerland |
Waystone Fund Services (Switzerland) SA Lausanne Phone: 0041213111781 |
Distributor(s) |
Bank am Bellevue AG Küsnacht Phone: +41 44 267 67 67 |
Asset Class | Equities |
EFC Category | |
Distribution Policy | Accumulation |
Home Country | Luxembourg |
Issuing Condition | Combination of issuing commission charged by the fund management company and transaction fee charged by the fund |
Redemption Condition | Combination of redemption commission charged by the fund management company and transaction fee charged by the fund |
Investment Strategy *** | The sub-fund is an equity fund. The investment objective of sub-fund is to achieve long-term capital growth by investing at least two thirds of the net assets of the fund in a portfolio of carefully chosen shares and other equity securities of companies that have their registered office or carry out the majority of their economic activity in the healthcare markets of emerging countries. |
Peculiarities |
Current Price * | 120.57 USD | 22.04.2025 |
---|---|---|
Previous Price * | 117.30 USD | 17.04.2025 |
52 Week High * | 139.34 USD | 04.10.2024 |
52 Week Low * | 108.93 USD | 09.04.2025 |
NAV * | 120.57 USD | 22.04.2025 |
Issue Price * | ||
Redemption Price * | ||
Closing Price * | ||
Indicative Minimum Price | ||
Fund Assets *** | 64,560,256 | |
Unit/Share Assets *** | ||
Trading Information SIX |
YTD Performance | +3.53% |
30.12.2024 - 22.04.2025
30.12.2024 22.04.2025 |
---|---|---|
YTD Performance (in CHF) | -5.77% |
30.12.2024 - 22.04.2025
30.12.2024 22.04.2025 |
1 month | +0.79% |
24.03.2025 - 22.04.2025
24.03.2025 22.04.2025 |
3 months | +4.84% |
22.01.2025 - 22.04.2025
22.01.2025 22.04.2025 |
6 months | -8.37% |
22.10.2024 - 22.04.2025
22.10.2024 22.04.2025 |
1 year | +5.60% |
22.04.2024 - 22.04.2025
22.04.2024 22.04.2025 |
2 years | -17.67% |
24.04.2023 - 22.04.2025
24.04.2023 22.04.2025 |
3 years | -17.21% |
22.04.2022 - 22.04.2025
22.04.2022 22.04.2025 |
5 years | -51.71% |
15.06.2021 - 22.04.2025
15.06.2021 22.04.2025 |
Equity Participation Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Share of Total Fund Assets in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Real Estate Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI Date |
Celltrion Inc | 7.04% | |
---|---|---|
Sun Pharmaceuticals Industries Ltd | 6.96% | |
BeiGene Ltd ADR | 6.84% | |
WuXi Biologics (Cayman) Inc | 5.13% | |
Samsung BioLogics Co Ltd | 4.50% | |
Akeso Inc Ordinary Shares | 3.63% | |
Sino Biopharmaceutical Ltd | 3.43% | |
Cipla Ltd | 3.33% | |
Rede d or Sao Luiz SA Ordinary Shares | 3.22% | |
Innovent Biologics Inc | 3.12% | |
Last data update | 31.03.2025 |
TER | 1.51% |
---|---|
TER date | 29.01.2021 |
Performance Fee *** | 0.00% |
PTR | |
Max. Management Fee *** | 0.90% |
Ongoing Charges *** | 1.38% |
SRRI ***
|
|
SRRI date *** | 31.03.2025 |